Clinical Trials Browser

Phase 2 × Carcinoma, Renal Cell × zimberelimab × Clear all

NCT07397611 2026-03-20

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Phase 2 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms